drugset / Trial / NCT00408993

Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China

NCT00408993

Phase 3 Completed 215 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.

Timeline

Start
2006-12
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral
Subject Duloxetine Small molecule 120 mg Oral

Indications